ATE310727T1 - Tetrahydrochinolinderivate mit selektiver aktivität für retinoid x rezeptoren - Google Patents
Tetrahydrochinolinderivate mit selektiver aktivität für retinoid x rezeptorenInfo
- Publication number
- ATE310727T1 ATE310727T1 AT03016595T AT03016595T ATE310727T1 AT E310727 T1 ATE310727 T1 AT E310727T1 AT 03016595 T AT03016595 T AT 03016595T AT 03016595 T AT03016595 T AT 03016595T AT E310727 T1 ATE310727 T1 AT E310727T1
- Authority
- AT
- Austria
- Prior art keywords
- carbons
- retinoid
- receptors
- alkyl
- selective activity
- Prior art date
Links
- 230000000694 effects Effects 0.000 title abstract 2
- 102000034527 Retinoid X Receptors Human genes 0.000 title 1
- 108010038912 Retinoid X Receptors Proteins 0.000 title 1
- 150000003530 tetrahydroquinolines Chemical class 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- SDVVLIIVFBKBMG-ONEGZZNKSA-N (E)-penta-2,4-dienoic acid Chemical group OC(=O)\C=C\C=C SDVVLIIVFBKBMG-ONEGZZNKSA-N 0.000 abstract 1
- 241001061127 Thione Species 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 125000003709 fluoroalkyl group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000004492 retinoid derivatives Chemical class 0.000 abstract 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Quinoline Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/164,949 US6048873A (en) | 1998-10-01 | 1998-10-01 | Tetrahdroquinolin-2-one 6 or 7-yl, tetrahdroquinilin-2-thione 6 or 7-yl pentadienoic acid and related derivatives having retinoid-like biological activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE310727T1 true ATE310727T1 (de) | 2005-12-15 |
Family
ID=22596785
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99970084T ATE246676T1 (de) | 1998-10-01 | 1999-09-21 | Tetrahydrochinolinderivate mit selektive aktivität für retinoid x rezeptoren |
| AT03016595T ATE310727T1 (de) | 1998-10-01 | 1999-09-21 | Tetrahydrochinolinderivate mit selektiver aktivität für retinoid x rezeptoren |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99970084T ATE246676T1 (de) | 1998-10-01 | 1999-09-21 | Tetrahydrochinolinderivate mit selektive aktivität für retinoid x rezeptoren |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6048873A (de) |
| EP (2) | EP1117648B1 (de) |
| JP (1) | JP2002526534A (de) |
| AT (2) | ATE246676T1 (de) |
| AU (1) | AU763108B2 (de) |
| CA (1) | CA2346037A1 (de) |
| DE (2) | DE69910231T2 (de) |
| DK (1) | DK1117648T3 (de) |
| ES (1) | ES2201835T3 (de) |
| WO (1) | WO2000020397A1 (de) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2335335A (en) * | 1998-03-13 | 1999-09-15 | Northern Telecom Ltd | Carrying speech-band signals over power lines |
| US6291677B1 (en) | 2000-08-29 | 2001-09-18 | Allergan Sales, Inc. | Compounds having activity as inhibitors of cytochrome P450RAI |
| US6313107B1 (en) | 2000-08-29 | 2001-11-06 | Allergan Sales, Inc. | Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI |
| US6388105B1 (en) * | 2001-09-27 | 2002-05-14 | Allergan Sales, Inc. | Benzofuran, indole or benzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors |
| US6720423B2 (en) | 2002-04-30 | 2004-04-13 | Allergan, Inc. | Dihydrobenzofuran and dihydrobenzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors |
| US7504508B2 (en) * | 2002-10-04 | 2009-03-17 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
| PL376156A1 (en) * | 2002-10-04 | 2005-12-27 | Millennium Pharmaceuticals, Inc. | Pgd2 receptor antagonists for the treatment of inflammatory diseases |
| US20090181966A1 (en) * | 2002-10-04 | 2009-07-16 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
| US6683092B1 (en) | 2003-04-09 | 2004-01-27 | Allergan, Inc. | [3-(c5-14alkyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-3-oxo-propenyl]-phenyl and [3-(c5-14alkyl-2-oxo-1,2,3,4- tetrahydro-quinolin-6-yl)-3-oxo-propenyl]-heteroaryl derivatives having anti-tumor activity |
| US6734193B1 (en) | 2003-06-03 | 2004-05-11 | Allergan, Inc. | (1,2,3,4-tetrahydroquinolin-8-yl)-heptatrienoic acid derivatives having serum glucose reducing activity |
| US6936636B2 (en) * | 2003-06-26 | 2005-08-30 | Allergan, Inc. | 5-[phenyl-tetrahydronaphthalene-2-yl dihydronaphthalen-2-yl and heteroaryl-cyclopropyl]-pentadienoic acid derivatives having serum glucose reducing activity |
| US6887896B1 (en) | 2003-10-29 | 2005-05-03 | Allergan, Inc. | 7-[(7-Alkoxy)-chrom-3-en-6-yl]-heptatrienoic acid and 7-[(3-alkoxy)-5,6-dihydronaphthalen-2-yl]-heptatrienoic acid derivatives having serum glucose reducing activity |
| US7476673B2 (en) * | 2003-12-30 | 2009-01-13 | Allergan, Inc. | Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptors |
| BRPI0608553A2 (pt) * | 2005-02-24 | 2010-01-12 | Millennium Pharm Inc | antagonistas de receptor de pgd2 para o tratamento de doenças inflamatórias |
| LT1937244T (lt) | 2005-09-30 | 2018-11-12 | Io Therapeutics, Llc | Vėžio gydymas specifiniais rxr agonistais |
| WO2007041077A2 (en) * | 2005-09-30 | 2007-04-12 | Janssen Pharmaceutica N.V. | Heterocyclic amide derivatives as rxr agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes |
| CA2624345A1 (en) * | 2005-09-30 | 2007-04-12 | Janssen Pharmaceutica N.V. | 1,2,3,5-tetrahydro-cyclopental[c]quinolin-4-one derivatives as rxr agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes |
| CN101316821A (zh) * | 2005-09-30 | 2008-12-03 | 詹森药业有限公司 | 作为rxr激动剂用于治疗异常脂肪血症、高胆固醇血症和糖尿病的二氢-[1h]-喹啉-2-酮衍生物 |
| US20070185055A1 (en) * | 2006-02-06 | 2007-08-09 | Guang Liang Jiang | Method for treating cachexia with retinoid ligands |
| US20090197878A1 (en) * | 2008-02-01 | 2009-08-06 | Wyeth | SUBSTITUTED BENZO[d][1,3]OXAZIN-2(4H)-ONES AND RELATED DERIVATIVES AND THEIR USES FOR MODULATING THE PROGESTERONE RECEPTOR |
| CN110151745A (zh) | 2011-12-13 | 2019-08-23 | Io治疗公司 | 使用rxr激动剂的自身免疫紊乱的治疗 |
| US10653650B2 (en) | 2011-12-13 | 2020-05-19 | Io Therapeutics, Inc. | Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists |
| BR122019007990B1 (pt) | 2013-11-18 | 2021-05-04 | Forma Therapeutics, Inc | Composto, e, composição farmacêutica |
| RU2720237C2 (ru) | 2013-11-18 | 2020-04-28 | Форма Терапеутикс, Инк. | Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет |
| KR102149321B1 (ko) | 2015-10-31 | 2020-08-28 | 아이오 테라퓨틱스, 인크. | Rxr 아고니스트와 갑상선 호르몬의 조합을 사용한 신경계 질환의 치료 |
| KR102549273B1 (ko) | 2016-03-10 | 2023-06-28 | 아이오 테라퓨틱스, 인크. | Rxr 작용제 및 갑상선 호르몬의 조합을 사용한 자가면역 질환의 치료 |
| NZ745704A (en) | 2016-03-10 | 2019-04-26 | Io Therapeutics Inc | Treatment of muscular disorders with combinations of rxr agonists and thyroid hormones |
| EP3684348A4 (de) | 2017-09-20 | 2021-08-18 | IO Therapeutics, Inc. | Behandlung von krankheiten mit estern von selektiven rxr-agonisten |
| KR102715396B1 (ko) | 2017-11-17 | 2024-10-08 | 아이오 테라퓨틱스, 인크. | 레티노이드 x 수용체 특이적 레티노이드의 제조를 위한 화합물 및 합성 방법 |
| US10966950B2 (en) | 2019-06-11 | 2021-04-06 | Io Therapeutics, Inc. | Use of an RXR agonist in treating HER2+ cancers |
| EP4444287A4 (de) | 2021-12-07 | 2025-05-28 | Io Therapeutics, Inc. | Verwendung eines rxr-agonisten und taxanen zur behandlung von her2+-krebs |
| KR20240115316A (ko) | 2021-12-07 | 2024-07-25 | 아이오 테라퓨틱스, 인크. | 약물 내성 her2+ 암 치료에서의 rxr 작용제의 용도 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5264578A (en) * | 1987-03-20 | 1993-11-23 | Allergan, Inc. | Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity |
| DE617614T1 (de) * | 1991-12-18 | 1995-06-08 | Baylor College Of Medicine, Houston, Tex. | Mitteln zur modulierung von verfahren durch retinoid rezeptoren und dafür nützliche verbindungen. |
| DE69333894D1 (de) * | 1992-04-22 | 2005-12-01 | Ligand Pharm Inc | Verbindungen mit Retinoid x rezeptorselektivität |
| ES2129115T3 (es) * | 1993-01-11 | 1999-06-01 | Ligand Pharm Inc | Compuestos que tienen actividad selectiva para los receptores de retinoides x, y medios para la modulacion de procesos mediados por receptores de retinoides x. |
| US5455265A (en) * | 1993-02-11 | 1995-10-03 | Allergan, Inc. | Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors |
| KR100363545B1 (ko) * | 1994-08-10 | 2003-02-19 | 에프. 호프만-라 로슈 아게 | 레틴산x-수용체리간드 |
| JP3826182B2 (ja) * | 1994-10-31 | 2006-09-27 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | モノ又はポリエンカルボン酸誘導体 |
| US5616712A (en) * | 1995-05-16 | 1997-04-01 | Allergan | Acetylenes disubstituted with a phenyl or heteroaryl group and a 2-thio-1,2,3,4-tetrahdroquinolinyl, 2-alkylthio-3,4-dihydroquinolinyl or 2-alkoxy-3,4-dihydroquinolinyl group having retinoid-like biological activity |
| US5675033A (en) * | 1995-06-06 | 1997-10-07 | Allergan | 2,4-pentadienoic acid derivatives having retinoid-like biological activity |
| US5776699A (en) * | 1995-09-01 | 1998-07-07 | Allergan, Inc. | Method of identifying negative hormone and/or antagonist activities |
| AU726450B2 (en) * | 1995-10-06 | 2000-11-09 | Ligand Pharmaceuticals Incorporated | Dimer-selective RXR modulators and methods for their use |
| AU7598596A (en) * | 1995-11-01 | 1997-05-22 | Allergan, Inc. | Sulfides, sulfoxides and sulfones disubstituted with a tetrahydronaphthalenyl, chromanyl, thiochromanyl or tetrahydroquinolinyl and substituted phenyl or heteroaryl group, having retinoid-like biological activity |
| US5739338A (en) * | 1996-11-05 | 1998-04-14 | Allergan | N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity |
-
1998
- 1998-10-01 US US09/164,949 patent/US6048873A/en not_active Expired - Fee Related
-
1999
- 1999-09-21 DK DK99970084T patent/DK1117648T3/da active
- 1999-09-21 AT AT99970084T patent/ATE246676T1/de not_active IP Right Cessation
- 1999-09-21 DE DE69910231T patent/DE69910231T2/de not_active Expired - Fee Related
- 1999-09-21 DE DE69928583T patent/DE69928583T2/de not_active Expired - Fee Related
- 1999-09-21 EP EP99970084A patent/EP1117648B1/de not_active Expired - Lifetime
- 1999-09-21 EP EP03016595A patent/EP1354878B1/de not_active Expired - Lifetime
- 1999-09-21 WO PCT/US1999/021857 patent/WO2000020397A1/en not_active Ceased
- 1999-09-21 AU AU60547/99A patent/AU763108B2/en not_active Ceased
- 1999-09-21 JP JP2000574514A patent/JP2002526534A/ja active Pending
- 1999-09-21 CA CA002346037A patent/CA2346037A1/en not_active Abandoned
- 1999-09-21 AT AT03016595T patent/ATE310727T1/de not_active IP Right Cessation
- 1999-09-21 ES ES99970084T patent/ES2201835T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1354878A3 (de) | 2003-12-10 |
| US6048873A (en) | 2000-04-11 |
| ATE246676T1 (de) | 2003-08-15 |
| DE69910231D1 (de) | 2003-09-11 |
| DE69928583D1 (de) | 2005-12-29 |
| EP1354878A2 (de) | 2003-10-22 |
| HK1057213A1 (en) | 2004-03-19 |
| ES2201835T3 (es) | 2004-03-16 |
| AU763108B2 (en) | 2003-07-10 |
| EP1354878B1 (de) | 2005-11-23 |
| HK1039121A1 (en) | 2002-04-12 |
| JP2002526534A (ja) | 2002-08-20 |
| DE69928583T2 (de) | 2006-08-10 |
| EP1117648B1 (de) | 2003-08-06 |
| DK1117648T3 (da) | 2003-11-17 |
| DE69910231T2 (de) | 2004-06-09 |
| EP1117648A1 (de) | 2001-07-25 |
| AU6054799A (en) | 2000-04-26 |
| WO2000020397A1 (en) | 2000-04-13 |
| CA2346037A1 (en) | 2000-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69928583D1 (de) | Tetrahydrochinolinderivate mit selektiver Aktivität für Retinoid x Rezeptoren | |
| EP1043317A4 (de) | Pyridazinderivate und dieselben als aktive bestandteile enthaltende medikamente | |
| DE3688374D1 (de) | Pyrazolsulfonamidderivat, verfahren zu seiner herstellung und dieses enthaltendes herbizid. | |
| FI982436A0 (fi) | Kondensoituneet heterosykliset yhdisteet | |
| KR950005827A (ko) | 신규 2- 아미노티아졸카르복사미드 유도체, 그의 제조방법 및 식물병원균 퇴치를 위한 그의 용도 | |
| DE69331414D1 (de) | Depsipeptide, herstellung und anwendung | |
| BR8704582A (pt) | Processo para preparar derivados de piridinacarboxamida | |
| NO981269D0 (no) | Forbindelser som forsterker virkningen av retinoider | |
| KR960703902A (ko) | 피라졸유도체 | |
| ATE164582T1 (de) | 1-methylcarbapenemderivate und verfahren zu ihrer herstellung | |
| DE69921151D1 (de) | Fluorszierende marker | |
| DK0783001T3 (da) | Androstenoner | |
| ATE73451T1 (de) | Verfahren zur herstellung von 3imidazolylmethyltetrahydrocarbazolonen. | |
| ATE73452T1 (de) | Verfahren zur herstellung von 3imidazolylmethyltetrahydrocarbazolonen. | |
| TW427979B (en) | A condensed piperidine compound | |
| KR920004353A (ko) | 4,5,6,7-테트라하이드로-3-아릴-인다졸, 그의 제조방법 및 제초제로의 용도 | |
| KR970704715A (ko) | 사카린 유도체(Saccharin Derivatives) | |
| ATE200779T1 (de) | Triazin-derivate | |
| ATE241594T1 (de) | N-phenylacetoacetamide und verfahren zu ihrer herstellung | |
| DE69815380D1 (de) | N,n'-bis (sulfonyl) hydrazine die als antineoplastische mittel nützlich sind | |
| KR840000530A (ko) | 신규 벤조트리아졸의 제조방법 | |
| EA200500032A1 (ru) | Производные ацилоксипирролидина и их применение в качестве лигандов v1b или v1b и v1a рецепторов | |
| KR930019598A (ko) | 인단-1,3-디온유도체 및 이들을 유효성분으로 함유한 제초제 | |
| KR920012100A (ko) | 비스포스폰산 유도체, 이의 제조 및 용도 | |
| KR890002015A (ko) | 2-니트로-5-(치환된 피리딜옥시)벤조히드록 심산 유도체 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |